A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia.

Trial Profile

A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Ofatumumab (Primary) ; Bortezomib
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014 as per ClinicalTrials.gov record.
    • 24 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top